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Abstract: Novel anti-cancer treatments have improved the survival rates of female young patients,
reopening pregnancy issues for female cancer survivors affected by the tumor treatment-related
infertility. This condition occurs in approximately one third of women of fertile age and is mainly
dependent on gonadotoxic protocols, including radiation treatments. Besides routine procedures
such as the hormonal induction of follicular growth and subsequent cryopreservation of oocytes
or embryos, the ovarian protection by gonadotropin-releasing hormone (GnRH) agonists during
chemotherapy as well as even gonadal shielding during radiotherapy, other innovative techniques are
available today and need to be optimized to support their introduction into the clinical practice. These
novel methods are hormone stimulation-free and include the ovarian cortex cryopreservation before
anti-cancer treatments and its subsequent autologous reimplantation and a regenerative medicine
approach using oocytes derived in vitro from ovarian stem cells (OSCs). For both procedures,
the major benefit is related to the prompt recruitment and processing of the ovarian cortex fragments
before gonadotoxic treatments. However, while the functional competence of oocytes within the
cryopreserved cortex is not assessable, the in vitro maturation of OSCs to oocytes, allows to select the
most competent eggs to be cryopreserved for fertility restoration.
Keywords: cryopreservation; gonadotoxicity; oncofertility; ovarian cortex; ovarian stem cells;
tissue biobanking
1. Introduction
Infertility has been recently assumed not only as a medical condition but also as a social disease,
which appears dependent on a series of pathogenic events sometimes related to the modern lifestyle,
since it is estimated to affect around 186 million people worldwide [1]. Besides the healthy couples
who experience chronic failure to conceive, young oncologic patients are also at high risk for infertility
which is primarily dependent upon adverse effects of anti-cancer treatments and is also frequently
permanent after the malignancy healing. In fact, since modern cancer treatments have undoubtedly
improved the therapeutic results and may lead to complete remission of the disease in a large number
of cases, in female cancer survivors under 45 years the quality of life may be fully restored only when
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pregnancies are possible [2]. Fertility preservation (FP) in oncologic patients is thus to be considered
today as a topic of primary importance.
Indeed, as a result of chemotherapies, radiotherapy, innovative treatments, or their combination,
a premature, significant depletion of the ovarian reserve (OR) may occur in at least one third of the
female cancer population, leading to a condition of permanent infertility [3–5]. To this, the international
guidelines for FP in oncology recommend an early personalized counseling for all patients in
reproductive age to screen if they are suitable candidates for FP programs in relation to the evaluation
of their OR. Therefore, multidisciplinary counseling among different specialists may thus be functional
in the management of young oncological female patients in order to preserve and restore their fertility
before gonadotoxic treatments and after their conclusion, respectively.
In this regard, several fertility preservation options ranging from routine to experimental strategies
are now available to counteract the treatment-related infertility risk. Besides the gonad shielding during
radiotherapy and the ovarian suppression by gonadotropin releasing hormone agonist (GnRHa) [6],
both the American Society of Clinical Oncology (ASCO) and the European Society for Medical
Oncology (ESMO) recommend the oocyte and embryo cryopreservation before anti-cancer treatment
as the mostly employed procedures able to guarantee motherhood in post-puberal female cancer
survivors [7,8]. These techniques require a controlled ovarian stimulation (COS) by gonadotropin
injections for at least 12 days to support the multiple follicular growth (MFG), in association with
repeated ultrasound examination and the evaluation of hormonal biomarkers such as estradiol. After
the ovulation induction, the retrieved oocytes are morphologically evaluated and cryopreserved as
mature eggs by slow-freezing or vitrification procedures [9], or can be fertilized in vitro and then stored
as embryos [8]. Although these cryopreservation procedures appear effective in terms of successful
pregnancies in healthy women [10], the preparative COS is not suitable in cases of pre-puberal girls
as well as in circumstances requiring urgent anti-cancer treatments as for hematologic malignancies
which cannot be retarded in relation to the time necessary to induce MFG. Furthermore, the additional
estrogen-related oncogenic risk in cases of estrogen-sensitive cancers such as breast or endometrial
tumors [11] renders COS not completely safe. To overcome these limitations, however, oogonial
cells may be retrieved as immature oocytes and, after their in vitro differentiation to mature eggs,
cryopreserved with the final purpose of avoiding the delay of urgent anti-cancer treatments [12].
An experimental ‘safe’ procedure independent from COS and menstrual cycle phases is the
cryopreservation of ovarian cortex fragments and their subsequent reimplantation after cancer healing.
This method appears suitable for both prepuberal and adult patients with functional OR, whose
ovarian biopsies are easily obtainable by laparoscopic or laparotomic surgery without COS and even
in conditions of anti-cancer treatment urgency. Within 24 hours, ovarian fragments are surgically
retrieved and cryopreserved using either slow freezing or vitrification [13]. Despite the advantages of
this technique and its suitability if compared to other FP methods, there are a few underestimated
aspects concerning the frequently inadequate pool of mature oocytes, the viability of eggs after thawing,
as well as the risk of implanting residual malignant cells originally resident in the frozen ovarian cortex,
such as leukemia cells [14].
In this context, the recent discovery of the ovarian stem cells (OSCs), first in animal models and
then in the human ovarian cortex, provided a novel approach potentially suitable to achieve FP in
oncological patients without the previously described concerns [15]. Once isolated from the ovarian
cortex and cultured in vitro, OSCs manifest an intrinsic potential to differentiate into mature oocyte-like
cells (OLCs) [16], thus providing new possibilities to replace hormone balancing in menopause as well
as to treat premature ovarian insufficiency (POI) induced by anti-cancer treatments and, eventually, for
further conditions causing female infertility.
Here, we revise the FP options for female cancer survivors focusing on the currently adopted
procedures as well as on innovative methods that could be prospectively proposed.
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2. Ovarian Structure and Components
Human ovaries originate from the intermediate mesoderm of the developing embryo. By week
four of gestation, the endodermal pluripotent cells generate the primordial germ cells (PGCs), that will
become the female germ cells [17]. The mechanisms underlying PGCs differentiation are not completely
elucidated and several bone morphogenetic proteins (Bmp) such as Bmp2 [18], Bmp4 [19–21] and
Bmp8b [20] are functionally involved in mammals. At the fifth week, PGCs proliferate by mitosis and
migrate to the gonadal ridge where they become oogonia [22,23], which actively replicate reaching a
peak of six to seven million cells at the 20th week [23] when they are surrounded by a layer of follicular
cells, namely the granulosa, thus forming the primordial follicle [24].
Germ cells gradually undergo a numeric decrease due to both apoptosis and follicle atresia which
provide the final oocyte pool resulting of approximately one to two million cells at birth, 300,000 cells at
puberty [25,26] and approximately 400 mature oocytes during the woman’s reproductive lifespan [27]
until the menopause [28,29].
A critical aspect of the age-related gradual decrease of the OR is the widespread opinion that
primordial follicles cannot be physiologically replaced during the woman’s reproductive life. This
dogma has been recently revisited in relation to the discovery of a population of OSCs capable of
generating new oocytes both in mice and in in vitro human models, although the physiological role of
these cells has still to be elucidated [30]. OSCs are located within the ovarian cortex, which constitutes
the anatomic site containing the major source of cells as hormones, soluble factors and structural
components required for mammalian oogenesis. In a recent study by Woods et al., indeed, it has been
hypothesized that the differentiation of OSCs to competent oocytes is directly supported by somatic
cells surrounding them in cortical niches [31] (Figure 1).
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Figure 1. Anatomic location and structure of the ovary including cortical components.
The cortex is the most organized tissue in the ovary and includes many follicles defined in their
developmental as primordial, primary, secondary and tertiary. The follicular cell layers, separated
from the oocyte by the zona pellucida, differentiate into granulosa cells (GCs) at the first stage, namely
the primary follicle, while stromal components of the ovary organize themselves into concentric layers
around the granulosa cells, forming the theca [32]. The granulosa in the secondary follicle becomes
multilayered and surrounds the oocyte while producing the follicular fluid within the antrum, thus
originating the cumulus oophorus inside antral follicles. Then, theca cells activate their steroidogenesis
and their products are converted to estrogens by granulosa cells.
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Cha et al., reported that a subset of immature cells which proliferate together with oocytes within
the developing follicles, namely undifferentiated granulosa cells (UGCs), also concur to regulate the
follicular final maturation resulting from their expression of stemness genes and related markers [33].
To support this, other investigators have expanded a somatic cell population showing stemness genes
as POU domain class-5 transcription factor-1 (Pou5f1) and Nanog from the ovarian cortex. These
cells exhibit a typical UGC molecular pattern as both Wingless-type MMTV integration site family
member 4 (Wnt4) genes, Forkhead box L2 (Foxl2) and Follicle stimulating hormone receptor (FSH-R).
These data suggested that granulosa stem cells as UGCs are functional during the ovarian life and are
perhaps implicated in supporting oogenesis and probably the OSC differentiation [4].
3. Current Techniques Using Cryopreserved Ovarian Cortex
Ovarian tissue cryopreservation (OTC) is a novel and alternative option for FP in female
cancer patients who urgently need chemotherapy, in particular with neoadjuvant protocols [34,35].
The retrieval of ovarian cortex fragments is slightly invasive and may also be applied to patients with
endometriosis [36], Turner’s syndrome [37], or to pre-pubertal girls with cancer [38].
Besides avoiding the COS by gonadotropin injections to support the MFG usually adopted for
the oocyte/embryo cryopreservation, the major advantage of using cryopreserved cortex includes its
feasibility independent from the menstrual cycle, both in pre-pubertal and adult cancer patients with
adequate OR previously evaluated, to acquire sufficient viable follicles from each cortical fragment.
The first case of successful human ovarian tissue transplantation was reported by Oktay et al., [39]
nearly 20 years ago. Subsequently, Donnez et al., [40] described the first live birth after
auto-transplantation of cryopreserved ovarian tissue in humans, and since then it is estimated
that more than 10,000 girls and women worldwide have undergone OTC resulting in more than 130
healthy newborns [41–43]. Published data are reported in Table 1 which summarizes both the pros and
cons of major FP procedures, including OTC that, however, is considered still experimental [44].
As depicted in Figure 2, at present there are three main options adopting the reimplantation of
cryopreserved ovarian tissue [45]: i) cortical pieces obtained from one or both ovaries replanted either
orthotopically or heterotopically [46]; ii) isolation and in vitro maturation (IVM) or activation (IVA)
of the recruited follicles using scaffolds [47,48]; and iii) whole ovary reimplantation with vascular
anastomosis [49,50]. Ovarian biopsy is usually performed by laparoscopy and cortical fragments of
approximately 5 mm are exposed to freezing solutions and stored in liquid nitrogen. Permeability to
cryoprotectants is essential to obtain viable oocytes after thawing and thin fragments are probably
better perfused. The oocyte content is related to the patient’s age and is expectedly consistent in girls.
Besides the simple OTC procedure, however, several drawbacks need to be addressed. The first is
related to the low number of viable oocytes after thawing the cortical fragments. In fact, removal of the
ovary from blood and oxygen supply, processing of the cortical tissue, freezing–thawing protocols
and transplantation may affect the survival of the follicle pool [51,52]. Freezing–thawing procedures,
indeed, lead to follicular pool decrease due to ice crystal formation which can induce cell injury in both
cytoplasmic organelles and cell membrane [53]. Thus, it is essential that OTC is primarily performed
by very slow freezing and quick thawing procedures to preserve the oocytes from the formation of
intra-cytoplasmic ice crystals [54]. On the other hand, unsuccessful OTC grafts are also dependent
on the follicular loss induced by early ischemia after transplantation, which is strongly related to
the oocyte cumulative injury promoted by biopsy, cryopreservation, defrosting of cortical pieces and
surgical reimplantation [55].
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Table 1. Schematic description of advantages and disadvantages of the major procedures adopted for fertility preservation (COS: Controlled ovarian hyperstimulation,
OR: ovarian reserve).




-High percentage of success
-Need for COS and cycle dependence
-Need to delay oncological treatment
-Oncogenic risk for hormonal-cancers
-Not applicable in females with poor OR
[7]. Loren AW et al, 2013.
[9] Parmegiani L et al, 2009.
[10]. Annan JJ et al, 2013
Embryo cryopreservation -Postpuberal women -Well established technique-Good percentage of success
-Need for COS and cycle dependence
-Need to delay oncological treatment
-Oncogenic risk for hormonal-cancers
-Not applicable in females with poor OR
-Limited to few countries
[8]. Peccatori FA et al, 2013.
[10]. Annan JJ et al, 2013.
[11]. Bianchii V et al, 2012
Ovarian cortex cryopreservation -Prepuberal women-Postpuberal women
-Immediate application
-No need for COS or cycle
dependence
-No oncogenic risk for hormone
sensitive cancers
-Experimental technique-Pelvic surgery
-Oncogenic risk after replantation
-Variable risk of unsuccess due to the
oocyte depletion in implanted fragments
-No possibility to select most
viable oocytes
-Limited to expert infertility centers
[34]. Jeruss J et al, 2009.
[35]. Andersen C et al, 2019.
[44]. Martinez F et al, 2015
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Figure 2. Potential applications of whole ovary and cortex fragments cryopreservation and
transplantation for fertility preservation.
Cryopreservation of a whole ovary followed by vascular anastomosis of the ovarian pedicle
has been suggested to decrease ischemic injury and provide a suitable follicular reserve as well as
longer lifespan of the transplant [56–58]. This procedural variant of OTC has been performed in a
small cohort of patients and, although providing encouraging results in humans [49,50], definitely
requires further studies, particularly in optimizing the freezing protocols, before its introduction into
the clinical practice.
Another variant is the implantation and grafting of isolated ovarian follicles. Dolmans et al.,
showed that isolated human follicles survive and grow for one week after xenograft using plasma
clots in mice [47]. Further, Amorim et al., observed that small pre-antral follicles from frozen–thawed
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tissue survive in vitro and increase their size after seven days of incubation in a three-dimensional
matrix of alginate hydrogel [48]. Although preliminary, these results support the in vitro culture of
isolated follicles from defrosted ovarian cortex as a suitable alternative to use of cryopreserved ovarian
tissue since it is also possible to select the follicles to be isolated and cultured in vitro. However, this
procedure is not free from potential damages deriving from both cryopreservation and thawing of the
ovarian biopsy fragments.
To optimize the freezing strategies, vitrification has been proposed as an alternative procedure.
This method is based on the induction of an ultra-rapid cooling process using high concentrations
of cryoprotectants, and is apparently functional in preventing cell injuries by producing a glass-like
amorphic state of cells, as well as in maintaining also stromal morphological and structural integrity
similar to fresh tissue [59–61]. Furthermore, Diaz-Garcia et al., evaluated the live birth rate following
oocyte vitrification with respect to OTC and transplantation in oncological patients undergoing
gonadotoxic treatments, and reported that that despite slightly higher results were achieved after
oocyte freezing, the vitrification would represent an alternative option for natural pregnancies when
oocyte cryostorage is not feasible [62].
More recently, utilization of slush nitrogen has been proposed to improve vitrification efficacy
since morphology, ultrastructure and viability of both follicles and stromal cells are apparently better
preserved in defrosted components, as compared with the same procedure using liquid nitrogen [63,64].
A further variant includes the IVM of immature oocytes aspirated just before the ovary specimen
freezing and cryostorage [65], that would be suitable for next use once maturated in vitro. Although
preliminary studies encourage this approach in fertility restoration programs, it appears inadequate
in cancer patients also for the risk of cancer relapse [66,67] induced by the hormonal stimulation in
patients with hormone sensitive cancers. In fact, the reintroduction of cancer cells with ovarian tissue
transplantation appears as a major drawback in patients with hematologic malignancies such as acute
leukemias, in which circulating leukemic cells are present in cryopreserved ovarian biopsies and can
cause reappearance of the disease after the procedure. Several reports definitely describe this risk in
patients with leukemia and lymphomas [68], for which autologous OTC and reimplantation is not
recommended in their FP program.
Finally, an ultimate addition to OTC has been recently proposed, namely the in vitro activation
of dormant follicles (IVA), to increase the number of mature oocytes promptly originated after
transplantation [69]. The procedure includes two steps after tissue thawing: the first is based on the
complete fragmentation of cortex biopsies in order to promote follicle growth and, at the same time,
the progression from secondary to early antral stage by disrupting the Hippo signaling pathway [70].
The second step involves the in vitro culture of cortical pieces with a mix of both PTEN inhibitor and
PI3K activator for 48 hours, in order to stimulate the activation of dormant primordial follicles [71].
This procedure has been reported by Suzuki et al., who successfully restored fertility in patients
diagnosed with POI after auto-grafting of vitrified human ovarian tissue coupled with follicle obtained
by the IVA method [72]. Considering the significant reduction of the ovarian lifespan and reproductive
potential of this approach, this fascinating strategy should be proposed mainly to women undergoing
OTC and reimplantation in more advanced fertile age [69].
Although these PF practices allow cancer patients to restore their fertility after the cancer healing,
there are still some limitations regarding their applicability. At present, in fact, it is not yet known
whether or not the efficacy of these procedures in cancer patients is comparable with the results
obtained in the healthy infertile population that have undergone the same treatments. On the other
hand, based on the poor literature in this regard it cannot be assumed that specific FP methods should
be separately suggested to defined histotypes of cancers. However, despite these unsolved questions
it appears preferable to avoid COS in hormone-dependent tumors as well as OTC in hematological
malignancies to prevent additional oncogenic risks of these procedures.
In conclusion, the OTC and reimplantation technique appears as a suitable method for FP in cancer
patients, obtaining a variable percentage of outcomes which reach approximately 25% of live births [73].
Int. J. Mol. Sci. 2020, 21, 3245 8 of 18
Figure 3 depicts the rate of live births by conventional procedures and utilization of cryopreserved
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techniques using ovarian cortex biopsies (right), as reported in literature.
However, although this FP method is independent from hormonal COS, menstrual timing and
is suitable for both pre-pubertal and adult patients with adequate OR, it is not free of applicative
restrictions, which prevalently include the impossibility to select the most competent eggs to be
fertilized, as currently accomplished by oocyte retrieval in infertility centres, and the risk of maligna t
cells reimplantati n, as occasionally experienced in hematologic maligna cies [68].
4. The Ovarian Cortex Transplantatio to Prevent the Cancer Treatme t Induced Infertility
Ovarian cortex cryopreservation is a suitable technique in pre-pubertal girls with cancer since
ovarian stimulation and in vitro fertilization are not feasible in these patients [74], implantation of
autologous cryopreserved cortex may functionally restore oogenesis and reproductive function [75].
The original application included the implantation of a fresh ovary into the forearm with vascular
anastomosis in a lymphoma patient undergoing pelvic irradiation [76], whereas in subsequent clinical
studies the follicular growth was also observed after implanting ovarian fragments without vascular
anastomosis [77]. The earliest case of ovarian restoration using cryopreserved human ovarian fragments
was reported in 2000 [39], although the first live births were obtained a few years later and supported
the efficacy of this procedure in fertility recovering [40,46,78].
In general, after thawing the fragments are implanted into residual ovaries or into a pelvic
peritoneum pocket within the ovarian fossa (orthotopic sites), or at distance from the ovary, at
subcutaneous sites (heterotopic sites). However, while follicular growth has been observed at both
orthotopic and heterotopic sites, almost all pregnancies and live births have been reported after
transplantation at an orthotopic site, which continues to be the first choice when applicable [43,79].
Indeed, there are only a few reports describing successful pregnancy and live births also in replanting
the cryopreserved ovarian tissue in heterotopic sites [80–82]. At present, however, more than 130
babies were born worldwide by using cryopreserved tissue and among them only very few resulted
from vitrified tissue [72], leading to intensive debate on the most fruitful method to be applied [83].
It is estimated that following the procedure of cryopreserved ovary transplant, the functional
recovery rate exceeds 90%, with a live birth rate per patient ranging from 18.2% to 40% in the
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literature [62,84–86]. However, differences detected between centers are likely due to the small cohorts
of patients enrolled in single studies, which also included differently aged female subjects since it has
been observed that the ovarian tissue cryopreserved before puberty or menarche would lead to better
results even when transplanted in advanced age [87,88].
Despite the evidence of this favorable outcome, the debate is today open whether or not to
define the procedure of ovary cryopreservation and transplantation as experimental. Ovarian tissue
cryopreservation is no longer considered experimental in Israel, while in Europe and USA its utilization
still needs to be regulated; almost all young cancer patients have been treated following dedicated
research protocols selecting those at high risk of gonadotoxicity related to radiation treatments,
chemotherapy and stem cell transplantation conditioning [89,90].
As mentioned, this procedure is at risk of re-introducing cancer cells. However, this risk is variable
in relation to the malignancy and its location, resulting higher risks in leukemia, Burkitt lymphoma,
neuroblastoma and ovarian cancer [91,92]. Also, it has been demonstrated that human ovarian tissue
containing cancer cells may transfer the disease into mice after xenograft [68]. By using molecular
approaches, several investigators demonstrated that more than 30% of the ovarian specimens from
patients with chronic myeloid leukemia, as well as 70% from acute lymphoblastic leukemia patients,
included variable amounts of leukemic cells. To prevent this risk, the ovarian tissue harvested during
the complete remission following first-line chemotherapy should be free of cancer cells and thus suitable
to be cryopreserved for future transplantation as shown in experimental xenograft models [93,94].
To reduce the cancer reimplantation risk, purging of tumor cells [95], isolation of follicles for
preparing disease-free follicle suspensions to be grafted as artificial ovary [96–98] and in vitro follicular
culture systems have been proposed [99]. Theoretically, the artificial ovary is a short-term substitute of
the natural ovary in which isolated follicles, ovarian stromal and endothelial cells in combination with
growth factors can be encapsulated within a biomaterial replacing the natural extra-cellular matrix
architecture before its surrounding cells undergo settlement within a new functional organ. This novel
application, however, needs to be fully investigated before its translation to the use in FP programs.
In contrast with the full ovary transplantation, the ovarian fragments implantation is performed
without vascular anastomosis and usually the number of primordial follicles decreases over 50% for the
concurrent tissue ischemia. The follicular depletion may thus significantly decrease the graft lifespan.
Once the neoangiogenesis is re-established, the lifespan of the tissue graft is variable, ranging from less
than 1 year to more than 10 years, and prompt neovascularization is apparently accelerated by intense
granulation within the transplantation site [79,100]. Therefore, it has been proposed that a preliminary
preparation of a peritoneal compartment one-week before the ovarian cortex reimplantation may
better support the neovascularization of fragments [40], whereas utilization of extracellular tissue
matrix would also produce a similar effect [101]. However, the benefit of these procedures has not
been established.
In more than 70% of women aged below 40 years with POI, residual ovarian follicles are detectable,
although in a dormant state. Thus, utilization of this resource has also been investigated and the
isolation of dormant follicles followed by their IVA has recently resulted in efficient follicle growth
detected in recipient ovaries as early as 20 days after the fragments’ implantation within the cortical
ovarian tissue [102,103].
Based on these considerations, the OTC and reimplantation procedure for FP includes both
advantages and drawbacks, particularly in oncology. Whilst it has been improved in technical
methodology for acquiring viable follicles as well for improving the grafting of implanted ovarian
biopsies, on the other hand the selection of follicles is based only on their ultrasound detection and the
quality of oocytes to be replanted is usually not investigated. Although the risk to regenerate certain
tumors in relation to the presence of cancer cells in the cryopreserved ovarian cortex can be limited by
selecting the best time for the biopsies, in which the tumor remission is evident, the procedure cannot
be considered completely safe at least in patients with hematologic neoplasias and some solid cancers.
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5. Ovarian Stem Cells (OSCs): A Novel Resource of the Ovarian Cortex
The discovery of functional adult stem cells named OSCs in ovarian cortex mammals has recently
revisited the paradigm of a fixed pool of oocytes, offering new therapeutic options in female infertility
also related to cancer treatment, in order to reduce risk of POF by the stemness technology. Their
identification, indeed, is in contrast with the central dogma in reproductive sciences that inherited
numbers of oocytes are not subjected to renewal after birth.
Previous studies proved the existence of OSCs in rats [16], pigs [104], non-human primates [105]
and in mice [106] by the expression of DEAD box polypeptide 4 (Ddx4) [107], a transmembrane
germline marker of oogonial differentiation which internalizes its COOH tale during final oocyte
maturation, in combination with other stemness markers (Fragilis, Stella, OCT4, SSEA4) [108].
Similar studies in women showed that OSCs were detectable also in ovarian cortex fragments
from healthy women both in pre and post-menopausal age [109]. The authors isolated the OSCs by
immunomagnetic separation by anti-human Ddx4 reagents, and generated cultures of the Ddx4+ cell
population also assessed for both FRAGILIS and SSEA4 markers. Their expansion in culture resulted
in large oocyte like cells (OLCs) sized up to 80 µm of diameter, whose intra-culture percent values were
almost comparable in cultures from menopausal and non-menopausal women. The OLCs subsequently
sorted by DEPArray methodology and investigated in their oocyte differentiation by droplet digital
PCR (ddPCR) revealed equivalent levels of GDF9 and SYCP3 mRNA as finally expressed genes in
both pre- and post-menopausal patients, thus supporting their final differentiation state of mature
oocytes [109]. By contrast, a small Ddx4+ cell population expressing DPPA3 mRNA, a marker of
immature oogonial cells undetected on OLCs, were also detected in the majority of cultures. Finally,
the progression of meiosis in haploid cells was also demonstrated by both DNA content [110] and
FISH analysis, revealing single signals on chromosome X and 5 [109] in terminally differentiated large
OLCs (Figure 4).
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Recently, Telfer and colleagues, showed that the reimplantation of OLCs in mice sterilized with
busulan resulted in oocyte repopulation of ovaries leading to fertilization and pregnancies [111], thus
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restoring the fertility by oocytes derived from OLCs. Thus, based on these data, there is enough
evidence that oocytes differentiated by human OSCs appear competent in vitro and these properties
need to be better ascertained for their future in vivo use also in humans. However, to obtain expanded
populations of oocytes it is necessary to pursue the investigative aspects as the identification of specific
oogenic factors acting during the final differentiation stage to mature eggs.
In this contest, UGCs capable to interact with newly generated oocytes and form primordial
follicles are suspected by Akahori et al., to prime the final oocyte maturation for their expression of
stemness markers and genes [4]. However, this appears controversial since UGCs probably derive from
pluripotent stem cells (PSC) which are resident in the ovaries and are inducible in vitro [112]. Thus,
in search of a model improving OSC differentiation to mature oocytes particularly in cancer-associated
infertility, several investigators as Anchan et al., suggest the utilization of patient-derived induced-PSCs
to generate autologous granulosa cells to induce aggregation of OSCs and OLCs with the purpose of
expanding the folliculogenesis in vitro and selecting the best mature oocytes [113].
Despite that the preliminary results on OSCs are promising, the stemness technology needs to
be further investigated and additional studies are needed in order to demonstrate the suitability of
these cells in humans and clarify the scientific scepticism on their potential to restore the oogenesis
with the purpose of guarantee its standardization and clinical application as a safe technique to restore
fertility also in oncological patients. In this specific field, the OSCs would become of primary interest
since they will be probably able to restore fertility in young patients without the hormone conditioning
with the additional advantage of exploring the quality of the eggs usable for FP thus acquiring the
characteristics of safe and selective procedure.
Another type of SCs is represented by the inducible pluripotent stem cells (iPSCs), which are
generated by the genic reprogramming of somatic cells into a pluripotent state. Like embryonic
stem cells, they are able to self-renew and differentiate. Scientists have engineered these iPSCs by
transfection in human somatic cells of four transcription factors, namely Nanog, Sox2, c-Myc and
Klf4, capable to revert the differentiated cells to embryonic-like state. Since these newly generated
cells show the morphology, pluripotency and capacity to generate teratomas like ESCs, the authors
defined these cells as “induced pluripotent stem cells”. However, while the ability to develop iPSCs
from differentiated somatic cells is quite affordable and exciting, the system has two major drawbacks.
Firstly, the reprogramming efficiency is low, suggesting that inside the cell there may be mechanisms
that prevent the reprogramming process; secondly, there is the oncogenic potential of iPSCs, as reflected
in their ability to form teratomas in mice. Thus, this revolutionary topic in the field has provided the
clinical and scientific communities a second tool for cell-based therapy [114].
6. Potential Utilization of OSCs for Female Fertility
Results from the basic research on OSCs open a direct issue on the safest FP procedure to be
suggested to young oncological female patients before any gonadotoxic treatment, since utilization of
OSCs in oncologic female patients may provide more advantages with respect to other procedures
currently applied to restore the ovarian reserve. Oocyte and embryo cryopreservation is largely
proposed to patients as the most successful procedure to obtain pregnancies after healing the cancer,
but the potential risk to stimulate the tumor by the hormonal burst with estrogens is commonly
under-evaluated and not well assessed in clinical studies. There are only few reports claiming this
risk [115], which is frequently ignored in planning FP programs in women with gynecologic cancers
for whom the ovarian suppression by GnRH agonists is apparently risk-free as compared to the
estrogen stimuli [4]. On the other hand, the few week-time period needed to induce MFG makes oocyte
cryopreservation sometimes inappropriate for patients immediately requiring neoadjuvant treatments.
Ovarian cortex cryopreservation and re-implantation should be undoubtedly considered a
procedure free of oncogenic hormone-induced risks, but the related drawbacks have been already
commented on in this article, and primarily concern the suitability of eggs located within the
cryopreserved ovarian cortex. The lack of a direct control on oocyte population before implanting
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the cryopreserved cortex, the unpredictable results in relation to the high variability of successful
outcomes, as well as the possibility that in selected tumors the grafted biopsy specimen may include
malignant cells capable to regenerate cancer, are topics of interest to be solved in the near future [92].
By contrast, the OSC technology would overcome these risks and restrictions. Furthermore,
in patients requiring urgent anti-cancer treatments, preventive laparoscopic biopsy of the ovarian
cortex would allow the isolation of OSCs with subsequent differentiation and expansion in vitro of
a large population of OLCs from which the highest quality and suitable cells could be selected for
freezing and cryostorage. The in vitro expanded OLCs are obtainable independently from the hormone
stimuli as well as from the menstrual phases, and their cryopreservation is based on the same protocols
adopted for the hormone-stimulated MFG and eggs recruitment. Overall, in contrast with the ovarian
cortex cryostorage and reimplantation, this practice allows to select the most viable oocytes to be
cryopreserved as well as to store high numbers of oocytes easily available for each patient.
In the regenerative medicine era, investigation of the OSC properties applied in the FP in oncology
is a very interesting field of clinical research and in our research institution we have in progress a similar
project in young oncologic patients undergoing abdominal surgery before gonadotoxic treatments,
with the purpose to identify the oogenic factor(s) involved in the final differentiation of OLCs to mature
eggs and optimize this technology for future translation to clinical use.
In conclusion, the OSC technology needs to be intensively investigated with the aim to offer to all
oncological patients undergoing anti-cancer treatments not only the safest method to avoid hormonal
stimuli capable of influencing the tumor progression or the replant of malignant cells, but also the
possibility to obtain in vitro and select the best oocytes for well-controlled fertility programs.
7. Conclusions
At present, the standard of care for young female cancer patient FP is the cryopreservation of mature
eggs and preimplantation embryos, which sometimes are not feasible procedures, due to the need
for urgent anti-cancer therapies or the personal history of a hormone-sensitive malignancy. Similarly,
other alternative and safer FP strategies include the support of the biobank for the cryopreservation of
ovarian cortex fragments for autologous transplantation, as well as for the storage of immature oocytes
for in-vitro maturation and fertilization, once the anti-cancer treatments have been completed, with
the aim to improve these methods in order to achieve a live birth rate comparable to that obtained by
traditional oocyte and embryo cryopreservation.
In this context, the ovarian cortex sampling and processing for Ddx4+ OSC isolation might
also enable their subsequent in-vitro maturation to OLCs for in-vitro fertilization procedures. This
technology, similarly to other FP strategies, also requires the biobank for the cryostorage of the most
viable oocytes derived from Ddx4+ OSCs to be fertilized and implanted in uterus. Based on these
innovative applications in terms of stemness in FP, it is desirable that this technique may undergo
rapid optimization and, hopefully, approval by competent authorities to consent expected maternity
projects in female patients who survived cancer but maintain the cancer treatment-induced infertility.
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GnRHa gonadotropin releasing hormone agonist
COS controlled ovarian stimulation
MFG multiple follicular growth
OSCs ovarian stem cells
OLCs oocyte-like cells
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Bmp2 bone morphogenetic protein 2
GCs granulosa cells
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